

Senolytics To sLOW Progression of Sepsis

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- Age 65 or older - Primary diagnosis of acute infection - Expected length of hospital stay at least 48 hours

Exclusion Criteria:

- No acute infection - Known hypersensitivity or allergy to Fisetin - Not admitted to hospital - Enrolled in another Sepsis clinical trial

Conditions & Interventions

Conditions:

Infectious Diseases

Keywords:

Fisetin, Sepsis

More Information

Description: Researchers hope that using Fisetin, an antioxidant, will reduce inflammation in the body caused by sepsis, which could help your body and organs have more time to recover. Placebo in this study will be something that looks similar to the study treatment, but does not contain any active drug. Everyone will receive 4 pills, but your group will determine how many of the pills are Fisetin. Researchers will look at the potential effects Fisetin or placebo has on inflammation in the body and how sick participants are at 7 days and 28 days.

Study Contact: Lauryn Barrett - barre998@umn.edu

Principal Investigator: Michael Puskarich

IRB

Number: SITE00001869

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.